FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women

The U.S. Food and Drug Administration has approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, the first generic version of Climara Pro, for eligible women with an intact uterus. The once-weekly hormone therapy is indicated to treat moderate to severe menopause-related hot flashes and other vasomotor symptoms, and to prevent postmenopausal osteoporosis.

The FDA announced the approval on October 20, 2026, saying it had granted approval the day before. The product is a transdermal system delivering 0.045 milligrams of estradiol per day and 0.015 milligrams of levonorgestrel. It is considered therapeutically equivalent to Climara Pro, the branded product made by Bayer. The agency did not provide a launch date or price, and directed consumers to the manufacturer for availability information.

Both medicines combine an estrogen and a progestogen in one patch. The FDA says the product is specifically approved for women with an intact uterus; its progestogen component is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. The approval does not mean the patch is suitable for every person experiencing menopause, and it should be used according to its prescribing information and a clinician’s advice.

The FDA lists several contraindications, including undiagnosed abnormal genital bleeding, breast cancer or a history of it, estrogen-dependent cancers, certain current or past blood clots, liver disease, and some blood-clotting disorders. Listed common adverse reactions, occurring in at least 5% of users, include application-site reactions, vaginal bleeding, breast pain, headache, back pain, depression, pain, upper respiratory infection and flu syndrome. The agency did not release patient-specific guidance beyond the product’s stated indications and warnings.

A New Generic Option for Menopause Care

The approval adds a generic option in a treatment category where patients and prescribers may weigh symptom relief, dosing, risks and cost. A once-weekly patch differs from daily pills and may suit some patients’ treatment routines, though the FDA’s approval announcement does not establish that it will improve adherence or be more affordable for every user.

The FDA said generic medicines can increase competition and help make treatment more affordable. It noted that nine out of 10 prescriptions filled in the United States are for generic drugs, but that broad statistic does not predict the price or savings for this specific product. Pharmacy coverage, manufacturer pricing and local availability may affect what patients pay.

For patients, the practical development is a newly approved generic equivalent to a branded combined-hormone patch, not a new indication or a change to the treatment’s safety warnings. Anyone considering hormone therapy should discuss their medical history and treatment options with a health professional, particularly given the listed contraindications.

How the Combined Patch Is Used

Climara Pro combines estradiol, an estrogen, with levonorgestrel, a progestogen, in a patch applied to the skin once a week. The FDA says the generic has the same active ingredients and is therapeutically equivalent to Climara Pro. Its approved uses are treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis in women with an intact uterus.

The uterus-specific qualification matters because estrogen used without a progestogen can raise the risk of endometrial hyperplasia, a thickening of the uterine lining. The FDA says the progestogen in this product is included to reduce that risk. This does not remove other risks or make the therapy appropriate for everyone; the agency lists conditions under which the medicine is contraindicated.

The announcement falls under the FDA’s stated public-health focus on expanding access to affordable medicines. The agency described the product as the first generic of Climara Pro. It did not say that the approval alone guarantees immediate access or a particular reduction in cost.

“Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible.”

— Acting FDA Commissioner Kyle Diamantas

Price and Launch Timing Are Unknown

The FDA’s announcement did not specify when the generic will reach pharmacies, what it will cost, or whether insurers will cover it differently from Climara Pro. The agency said consumers should contact Zydus Pharmaceuticals for availability information. No details were provided about planned distribution or expected savings.

The release also did not provide comparative pricing, patient-outcome data or evidence that the weekly patch will be more convenient or effective for any particular individual. FDA therapeutic-equivalence approval identifies the generic as equivalent to the branded product; it does not establish that every patient will respond the same way or that the medicine is appropriate for people with the listed contraindications.

Manufacturer to Confirm Availability

Zydus Pharmaceuticals is the source the FDA identified for information about when the generic will be available. Patients and clinicians can also consult the FDA’s approved drug products listing, known as the Orange Book, for product and therapeutic-equivalence information as it is posted.

Any decision to start or switch hormone therapy should be made with a qualified health professional, who can review the patient’s symptoms, medical history, risks and alternatives. Further details on launch timing, pharmacy supply and pricing may emerge from the manufacturer, pharmacies or insurers; none was included in the FDA release.

Key Questions

What did the FDA approve?

The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel transdermal system, the first generic version of Climara Pro.

How often is the patch applied?

The patch is applied once a week. It contains estradiol and levonorgestrel in a single transdermal system.

Who is the generic patch approved for?

Its approved uses are treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis in women with an intact uterus. A clinician can determine whether it is appropriate for an individual.

Is the generic available now, and how much will it cost?

The FDA announcement did not give a launch date or price. It advised consumers to contact Zydus Pharmaceuticals for availability information.

What safety issues did the FDA list?

The FDA lists contraindications including certain cancers, unexplained genital bleeding, some current or past blood clots, liver disease and clotting disorders. Common adverse reactions include application-site reactions, vaginal bleeding, breast pain and headache. Patients should review the prescribing information with a health professional.

Source: primary